Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, P.R. China, 36 Sanhao Street, Heping District, 86110004.
Cardiol J. 2020;27(3):262-271. doi: 10.5603/CJ.a2018.0097. Epub 2018 Sep 20.
Thyroid hormones profoundly influence the cardiovascular system, but the effects of mild thyroid dysfunction on the clinical outcome of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) are not well defined. This study aimed to determine the effect of mild thyroid dysfunction on 12-month prognosis in ACS patients undergoing PCI.
In this prospective cohort study with a 12-month follow-up, 1560 individuals were divided into four groups based on thyroid hormone levels upon admission: euthyroidism (used as a reference group), subclinical hypothyroidism, subclinical hyperthyroidism, and low triiodothyronine syndrome (low T3 syndrome). The outcomes measured were all-cause mortality, cardiac mortality, nonfatal rein-farction, and unplanned repeat revascularization.
In this study, the prevalence of mild thyroid dysfunction was 10.8%. Multivariate analysis showed that low T3 syndrome, but not subclinical hypothyroidism or subclinical hyperthyroidism, was associated with a higher rate of all-cause (HR 2.553, 95% CI 1.093-5.964, p = 0.030) and cardiac mortality (HR 2.594, 95% CI 1.026-6.559, p = 0.034), compared with the euthyroidism group.
Mild thyroid dysfunction was frequent in patients with ACS undergoing PCI. Low T3 syndrome was the predominant feature and was associated with 12-month adverse outcomes in these patients.
甲状腺激素对心血管系统有深远影响,但轻度甲状腺功能障碍对行经皮冠状动脉介入治疗(PCI)的急性冠状动脉综合征(ACS)患者临床结局的影响尚未明确。本研究旨在确定 ACS 患者行经皮冠状动脉介入治疗后轻度甲状腺功能障碍对 12 个月预后的影响。
在这项前瞻性队列研究中,对 1560 名患者进行了 12 个月的随访,根据入院时的甲状腺激素水平将其分为四组:甲状腺功能正常(作为参考组)、亚临床甲状腺功能减退、亚临床甲状腺功能亢进和低三碘甲状腺原氨酸综合征(低 T3 综合征)。测量的结果是全因死亡率、心脏死亡率、非致死性再梗死和计划外再次血运重建。
在这项研究中,轻度甲状腺功能障碍的患病率为 10.8%。多变量分析显示,与甲状腺功能正常组相比,低 T3 综合征(HR 2.553,95%CI 1.093-5.964,p = 0.030)和心脏死亡率(HR 2.594,95%CI 1.026-6.559,p = 0.034)的发生率更高,但亚临床甲状腺功能减退或亚临床甲状腺功能亢进则不然。
ACS 患者行经皮冠状动脉介入治疗后甲状腺功能障碍较为常见。低 T3 综合征是主要特征,与这些患者 12 个月的不良结局相关。